Table 7. Response by CTCL Subtype.
CTCL Subtype | ORR | CR | PR |
---|---|---|---|
All evaluable patients (N=33)* | 20 (61%) | 4 (12%) | 16 (48%) |
MF (n=19) | 12 (63%) | 2 (11%) | 10 (53%) |
Transformed MF (n=10) | 5 (50%) | 1 (10%) | 4 (40%) |
Sézary syndrome (n=3) | 2 (67%) | 0 (0) | 2 (67%) |
ALCL (n=1) | 1 (100%) | 1 (100%) | 0 (0) |
Stage of MF Responders | IIB, IVA2(2) | t-IA;IB(3);IIa (3); IIb(7); & III;IVA1;IVB (1) |
Included all patients who received at least 1 dose of pralatrexate or bexarotene and had a baseline response evaluation t = transformed